Innovent Biologics First Half 2024 Earnings: CN¥0.24 loss per share (vs CN¥0.091 loss in 1H 2023)

Simply Wall St · 08/31 01:13

Innovent Biologics (HKG:1801) First Half 2024 Results

Key Financial Results

  • Revenue: CN¥3.95b (up 46% from 1H 2023).
  • Net loss: CN¥392.6m (loss widened by 182% from 1H 2023).
  • CN¥0.24 loss per share (further deteriorated from CN¥0.091 loss in 1H 2023).
earnings-and-revenue-growth
SEHK:1801 Earnings and Revenue Growth August 31st 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

Innovent Biologics Earnings Insights

Looking ahead, revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 27% growth forecast for the Biotechs industry in Hong Kong.

Performance of the Hong Kong Biotechs industry.

The company's shares are down 2.3% from a week ago.

Risk Analysis

It is worth noting though that we have found 1 warning sign for Innovent Biologics that you need to take into consideration.